NattoPharma is proud to announce that its complete line of MenaQ7®Vitamin K2 as MK has received verification from the Non-GMO Project,a non-profit 501(c)3 organization that offers North America’s only third party verification and labeling for non-GMO (genetically modified organism) food and products.

“MenaQ7 has always been non-GMO, yet obtaining Non-GMO Project verification helps reinforce our commitment to our partners, who seek to offer the safest, healthiest finished products available,” says Eric Anderson, senior vice president of global sales and marketing with NattoPharma.

“Consumers are actively seeking out non-GMO products, so having the Non-GMO Project verify our line in accordance with their standard provides our partners an added level of support they rightfully expect,” Anderson continues. “Further, it perpetuates MenaQ7’s reputation as being the leading Vitamin K2 as MK-7 brand.”

For more information, visit the Non-GMO website

About MenaQ7®

MenaQ7® is the best documented, commercially available vitamin K2 as MK-7 with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. MenaQ7® is available in two varieties: natural vitamin K2 as MK-7 Crystals and nature-identical synthetic vitamin K2 as MK-7 PURE. For more information on the health benefits of MenaQ7, visit menaq7.com.

About NattoPharma

NattoPharma ASA, based in Norway, is the  world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, and has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Meuchen, NJ. For more information, visit nattopharma.com.

For more information, please contact:

Kate Quackenbush, Director of Communications
NattoPharma USA, Inc.
Phone: 609-643-0749
E-mail: kate.quackenbush@nattopharma.com